Carrie Mann’s kidney cancer journey
This is a guest post by Carrie Mann, 48, a stage 4 kidney cancer patient from West Virginia. My name is Carrie Mann. I am a 48-year-old mother of two from southern West Virginia, a…
This is a guest post by Carrie Mann, 48, a stage 4 kidney cancer patient from West Virginia. My name is Carrie Mann. I am a 48-year-old mother of two from southern West Virginia, a…
This is a guest post by Jeff Kallis, who was diagnosed with stage 3 clear cell renal cell carcinoma in 2023. Jeff has since written a book about his experience, One Kidney: Dealing with Kidney…
This is a guest post by Dr. Pavlos Msaouel, a medical oncologist and researcher at MD Anderson Cancer Center, renal medullary carcinoma expert, and member of the KCA’s Medical Steering Committee. Dr. Msaouel has also…
I’m excited to highlight a new study spearheaded by Dr. Ritesh Kotecha from Memorial Sloan Kettering Cancer Center that describes how renal cell carcinoma (RCC) patients’ genetic ancestry (GA) – which is the information about…
UPDATE: Kidney Cancer Unfiltered is live! Listen here: We are excited to bring you a groundbreaking new podcast series called “Kidney Cancer Unfiltered”. Hosted by Annamaria Scaccia, a member of the Kidney Cancer Association’s Patient…
This is a guest post by Joel Stern, member of the KCA’s Board of Directors, author of “My Journey With Stage IV Renal Cell Carcinoma”, and serves as a peer mentor with KCA partner Imerman…
Claudia Tatum, a member of the Kidney Cancer Association’s Patient & Caregiver Advisory Council, spoke with Bruce Morton on the Cancer Interviews podcast about being diagnosed with a rare form of renal cell carcinoma, survivorship,…
The 2023 International Kidney Cancer Symposium: North America will feature three special awards honoring standout members of the kidney cancer community. The meeting will take place in Nashville, Tennessee from November 9-11. Register now.
We rounded up a few research highlights from the 2023 Congress of the European Society for Medical Oncology (ESMO), held recently in Madrid, Spain. Two new first-line treatment immunotherapy options Toripalimab is a new immunotherapy infusion, a…
Three analyses of the LITESPARK trial examining the hypoxia-inducible factor 2a (HIF-2a) belzutifan (Welireg) showed efficacy and benefit for this novel therapy over comparator treatments in advanced clear cell renal cell carcinoma (RCC) as well…